<DOC>
	<DOCNO>NCT00396357</DOCNO>
	<brief_summary>This study design evaluate efficacy safety vildagliptin combination metformin 500 mg bid compare metformin 1000 mg bid patient type 2 diabetes .</brief_summary>
	<brief_title>Efficacy/Safety Vildagliptin Metformin Combination Therapy Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1878 year inclusive Type 2 diabetes diagnosis least 2 month prior study entry Body mass index range 2245 kg/m2 HbA1c range 6.5 9 % inclusive Fasting plasma glucose &lt; 270 mg/dL ( 15 mmol/L ) A history type 1 diabetes Evidence significant diabetic complication Treatment insulin oral antidiabetic agent Congestive heart failure require pharmacologic treatment Clinically significant renal dysfunction define metformin label criterion ( serum creatinine level &gt; /= 1.5 mg/dl ( male ) &gt; /= 1.4 mg/dl ( female ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>hemoglobin A1c</keyword>
	<keyword>metformin</keyword>
</DOC>